Correlation Between Molecular Partners and Neoleukin Therapeutics
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Neoleukin Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Neoleukin Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Neoleukin Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Neoleukin Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Neoleukin Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Neoleukin Therapeutics.
Diversification Opportunities for Molecular Partners and Neoleukin Therapeutics
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Molecular and Neoleukin is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Neoleukin Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neoleukin Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Neoleukin Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neoleukin Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Neoleukin Therapeutics go up and down completely randomly.
Pair Corralation between Molecular Partners and Neoleukin Therapeutics
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.27 times more return on investment than Neoleukin Therapeutics. However, Molecular Partners is 1.27 times more volatile than Neoleukin Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Neoleukin Therapeutics is currently generating about -0.06 per unit of risk. If you would invest 684.00 in Molecular Partners AG on September 1, 2024 and sell it today you would lose (102.00) from holding Molecular Partners AG or give up 14.91% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 8.33% |
| Values | Daily Returns |
Molecular Partners AG vs. Neoleukin Therapeutics
Performance |
| Timeline |
| Molecular Partners |
| Neoleukin Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Molecular Partners and Neoleukin Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and Neoleukin Therapeutics
The main advantage of trading using opposite Molecular Partners and Neoleukin Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Neoleukin Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neoleukin Therapeutics will offset losses from the drop in Neoleukin Therapeutics' long position.| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
| Neoleukin Therapeutics vs. CytomX Therapeutics | Neoleukin Therapeutics vs. Spero Therapeutics | Neoleukin Therapeutics vs. Instil Bio | Neoleukin Therapeutics vs. NextCure |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |